Company profile

Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy: Bristol-Myers Squibb in the cancer field and Novo Nordisk in the inflammation signs. Net sales break down by source of income as follows:
  • income from partnership and licensing agreements (74.1%);
  • federal subsidies (25.9%).
At the end of 2019, the company held a portfolio of 3 products in clinical development including 2 in phase II (IPH4102 for the treatment of cutaneous T-cell lymphomas and Monalizumab for the treatment of cancer) and 1 in phase I (IPH5401 for the treatment of solid tumors), and 7 in preclinical development phase (treatment of cancer and inflammatory diseases).

Source: Cofisem - Last Update: 28 May 2020
Key Executives
Chairman of the Management Board Mondher Mahjoubi
Member of the Management Board Laure-Hélène Mercier
Member of the Management Board Yannis Morel
Chief Financial Officer Laure-Hélène Mercier
VP, Communication Tracy Rossin
Human Resources Director Odile Laurent
Source: Cofisem - Last Update: 27 May 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 85,814 93,952 44,033 65,721 25,141
Income from ordinary activities 85,814 93,952 44,033 65,721 25,141
Operating income -27,052 5,146 -39,983 7,571 -10,772
Cost (net) of financial indebtedness 1,416 1,480 1,141 1,758 879
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -20,759 3,049 -48,385 12,640 -6,706
Net income (Group share) -20,759 3,049 -48,385 12,640 -6,706
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 28 May 2020
Shareholder information
Flottant 59.80 %
Novo Nordisk A/S 12.50 %
AstraZeneca 9.50 %
EcoR1 8.40 %
Bpifrance Participations 8.10 %
Employees 1.60 %
Source: Cofisem - Last Update: 27 May 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Innate Pharma

117 Avenue de Luminy
BP 30191
FR-13009 Marseille
France
Source: Cofisem - Last Update: 28 May 2020

Contact

Jérôme Marino
Phone number: +33 (0)4 84 90 31 91
Source: Innate Pharma - Last Update: 28 May 2020